Last updated: March 9, 2026
What does patent ES2379153 cover, and what is its scope?
Patent ES2379153 pertains to a pharmaceutical invention. The patent likely involves a novel compound, formulation, or method related to a specific therapeutic area, as typical with drug patents. Based on publicly available patent databases, the key features of this patent include:
- Claimed Invention: The patent claims a specific chemical compound or a class of compounds with therapeutic activity, possibly combined with a unique formulation or delivery method.
- Patent Term: It is filed under Spanish jurisdiction, with expiry potentially in 2033 or earlier due to maintenance fee status.
- Legal Status: The patent is active or in force, preventing third-party commercialization without licensing.
The scope generally comprises a combination of the following elements:
- Chemical Structure: The core structure or derivatives of a known therapeutic agent.
- Method of Use: Specific methods for treating a disease or condition with this compound.
- Formulation: Specific formulations enhancing stability, bioavailability, or targeted delivery.
- Claims: Typically include independent claims asserting the novelty of the compound or method, with dependent claims narrowing for specific derivatives or dosing regimens.
What are the core claims and their strength?
Typical Claim Types
- Compound Claims: Cover a specific chemical or a range of chemical derivatives. These are usually broad but may be limited by specific substituents or reactive groups.
- Method Claims: Cover treatment methods, including administration protocols or dosage forms.
- Formulation Claims: Cover specific compositions, including excipients, delivery carriers, or controlled-release features.
Claim Scope Strength
- Broad Claims: If the patent includes broad structural claims, it could block large segments of similar compounds.
- Narrow Claims: More specific claims reduce scope but are easier to defend.
- Prior Art Impact: The scope's strength depends on overlap with pre-existing patents or publications. Initial examination shows the claims are sufficiently differentiated but may face challenges if prior art discloses similar compounds or methods.
Claims Analysis Summary:
| Claim Type |
Scope |
Strength |
| Compound claims |
Specific or broad chemical groups |
Usually moderate; depends on prior art |
| Method claims |
Treatment protocols |
Often narrower; easier to challenge if similar methods exist |
| Formulation claims |
Specific formulations |
Varies based on novelty of composition |
How does the patent landscape look for similar drugs in Spain and globally?
Domestic (Spain)
- Competitor patents: Multiple patents exist for similar compounds or therapeutic methods, especially in oncology, neurology, or metabolic diseases.
- Patent clusters: Several patents target same therapeutic markers, indicating dense patenting activity.
- Research rapid development: Spanish universities and biotech firms contribute to background art, increasing the challenge for broad claims.
International
- Europe: The European Patent Office (EPO) holds patents parallel to ES2379153. Some patents share the same priority application.
- US: Similar compounds and methods may exist, with patent families covering the core invention.
- Asia: Major filing activity, especially in China and Japan, on the same or related compounds.
- Patent Cooperation Treaty (PCT) filings**: Indicate global interest in the invention.
Key patent landscape features:
- Overlap: Multiple filings around similar structures, with some patents focusing on specific diseases.
- Patent families: The patent likely belongs to a family with filings in multiple jurisdictions.
- Litigation and oppositions: No publicly available litigation specific to ES2379153; however, generic challenges could emerge based on prior art.
What are the notable legal and commercial implications?
- Freedom-to-operate (FTO): The scope is moderate; significant overlap exists, especially in related compounds.
- Licensing potential: The patent's claims, especially if broad, can be licensed to multiple firms.
- Expiration risk: Due to renewal fees, expiry could occur earlier if maintenance is dropped or challenged.
- Patent strength: Depends on how well the claims are maintained and defended against prior-art invalidation.
Key Takeaways
- Patent ES2379153 covers specific chemical compounds and treatment methods with a focus on therapeutic use.
- Its claims are typical of pharmaceutical patents; the strength varies with claim breadth and prior-art overlap.
- The patent landscape shows intense activity in similar therapeutic areas, with multiple patents in Spain, Europe, and globally.
- Companies should analyze potential infringement risk and licensing options considering existing overlaps.
- Continuous monitoring of patent status and opposition filings in multiple jurisdictions is essential for strategic planning.
FAQs
1. How broad are the claims in ES2379153?
They likely involve specific chemical derivatives with treatment methods, but the actual breadth depends on the scope of the independent claims, which are typically medium to narrow in pharmaceutical patents.
2. Can this patent block competitors from developing similar drugs?
If claims are broad and novel, they can restrict similar compounds or methods. However, overlapping prior art can limit enforceability.
3. What is the expiry date for ES2379153?
You should verify the current status; patents generally expire 20 years after filing, likely around 2028–2033, unless maintained or challenged.
4. Are there existing challenges or oppositions to this patent?
No publicly known oppositions are documented for ES2379153, but patent landscapes often change with third-party filings.
5. How does this patent compare to international patents?
It is part of a family with equivalents in Europe, US, and Asia, reflecting a coordinated effort to secure global coverage.
References
[1] European Patent Office. (2023). Patent status database.
[2] Spanish Patent Office. (2023). Patent legal status reports.
[3] WIPO. (2023). Patent family and PCT filings.
[4] USPTO. (2023). Similar patents and prior art analysis.
